<DOC>
	<DOCNO>NCT01958190</DOCNO>
	<brief_summary>In study compare long term renal function liver transplantation recipient treat standard dose extended-release tacrolimus alone recipient treat combination low dose extended-release tacrolimus low dose sirolimus . The hypothesis patient treat combination well long term renal function patient treated standard dose tacrolimus alone .</brief_summary>
	<brief_title>Study Comparing Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus &amp; Sirolimus</brief_title>
	<detailed_description>To evaluate effectiveness safety concentration control combination daily dose low-dose sirolimus ( trough level : 3-5 ng/ml ) extended-release tacrolimus ( trough levels:3-5 ng/ml ) , order provide superior renal function maintain comparable rate patient graft survival , compare concentration control - daily extend release tacrolimus ( trough level : 5-10 ng/ml ) 12 , 24 36 month post-transplant . Moreover , compare incidence de novo malignancy , quality life , fatigue side effect treatment arm . 2.1 Primary objective : To evaluate effectiveness safety concentration control combination low-dose sirolimus ( trough level : 3-5 ng/ml ) extended-release tacrolimus ( trough level : 3-5 ng/ml ) , order provide superior renal function maintain comparable rate patient graft survival , compare concentration control - daily extend release tacrolimus ( trough level : -10 ng/ml ) control 12 , 24 36 month post-transplant . 2.2 . Secondary objective : - To compare incidence de novo recurrence cancer study arm control arm 36 month . - To compare incidence severity biopsy proven acute rejection study arm control arm 12 , 24 36 month . - To evaluate renal function 12 , 24 36 month ( calculate GFR ) . - To evaluate development new onset diabetes mellitus 12 , 24 36 month post transplant - To evaluate prevalence CNI side effect 12 , 24 36 month - To evaluate quality life ( Eq5D ) fatigue severity score 12 , 24 36 month - To evaluate percentage patient combination tacrolimus sirolimus convert back tacrolimus mono-therapy .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Primary liver transplantation retransplantation within 14 day first transplantation Use Advagraf least 2 week prior randomization Patent hepatic artery Closed abdominal wound Stable graft function Positive inform consent time randomization Age 1870 year Treatment investigational drug within 3 month start therapy Multi organ transplantation cGFR &lt; 30 ml/min Proteinuria &gt; 800 mg/24 h Hyperlipidemia refractory optimal medical management ( Cholesterol &gt; 9 mmol/l and/or triglyceride &gt; 8.5 mmol/l ) . Patients control hyperlipidemia acceptable time randomization . Known hypersensitivity sirolimus derivative Thrombocytes &lt; 50 x 109 /L Leukocytes &lt; 2.5 x 109 /L Haemoglobin &lt; 6 mmol/L Biopsy prove rejection 2 week prior randomization HIV positivity Signs recurrent de novo cancer Patients nonHCC malignancy within past 5 year ( exclude successfully treat squamous cell carcinoma basal cell carcinoma skin ) Evidence significant local systemic infection Pregnancy breast feed Women childbearing potential willing take oral contraception Any condition opinion investigator would make patient unsuitable enrollment , could interfere patient participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Liver transplantation long term renal function</keyword>
	<keyword>tacrolimus sirolimus</keyword>
</DOC>